newsfilter
← Latest News
ACCESS Newswire·

Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases

JACKSON CENTER, PA / ACCESSWIRE / January 13, 2022 / Halberd, Inc. (OTC:HALB) ("HALB" or the "Company"), an innovative biotech company focused on developing treatments for difficult-to-cure debilitating diseases, today announces that they have been able